Drugmakers of insulin accused of price fixing
Three of the biggest makers of diabetes treatments have been accused of price fixing. A lawsuit filed this week claims that Sanofi, Novo Nordisk and Eli Lilly have been conspiring to drive up prices of insulin at the expense of their patients. Because of the high prices, the suit says some patients have been using expired insulin or starving themselves to control their blood sugar. The drug makers say the allegations have no merit.
Click the above audio player to hear the full story.
Stories You Might Like
There’s a lot happening in the world. Through it all, Marketplace is here for you.
You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible.
Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.
